Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 14/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 14/20 | 0.49 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1272279 | 0.89 | NR1H2 (0.48) | NR1H2NR1H3CRHR1 | |
| SCHEMBL1271040 | 0.84 | NR1H2 (0.67) | NR1H2NR1H3 | |
| SCHEMBL1271065 | 0.82 | NR1H2 (0.46) | NR1H2NR1H3PDE10A | |
| SCHEMBL1272181 | 0.82 | NR1H2 (0.56) | NR1H2NR1H3CRHR1 | |
| SCHEMBL1272165 | 0.82 | NR1H2 (0.67) | NR1H2NR1H3 | |
| SCHEMBL1272150 | 0.81 | NR1H2 (0.78) | NR1H2NR1H3 | |
| SCHEMBL1271106 | 0.79 | NR1H2 (0.79) | NR1H2NR1H3 | |
| SCHEMBL1272198 | 0.79 | NR1H2 (0.49) | NR1H2NR1H3CRHR1HTR3EHTR3B | |
| SCHEMBL1272009 | 0.79 | NR1H2 (0.79) | NR1H2NR1H3 | |
| SCHEMBL1272280 | 0.78 | NR1H2 (0.78) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034526-A1 | Benzimidazole Compounds | WYETH LLC (US) | 2011-02-10 | — | — | US | disclosed |
| EP-2231617-A1 | BENZIMIDAZOLE COMPOUNDS | Wyeth LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009086138-A1 | BENZIMIDAZOLE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034526-A1 | Benzimidazole Compounds | NR1H4, NR1H2, NR1H3 | NR1H2 2/4885NR1H3 3/4885CRHR1 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.